Associations between Human Aldosterone Synthase (CYP11B2) and Angiotensin II type 1 Receptor (ATR1) Gene Polymorphisms with End Stage Renal Disease In hypertensive Egyptian Patients on Maintenance Hemodialysis

Authors

  • Maha Moustafa Kamal Lecturer of biochemistry
  • Omayma M Hassanin Assistant consultant of clinical pathology and molecular pathology
  • Ezzat Abdel-Rahman El Etreby Professor of internal medicine and nephrology
  • Tarek M El Masry Assistant consultant of biochemistry and clinical pathology

Keywords:

End stage renal disease, CYP11B2 C-344T, ATR1 A1166C, gene polymorphisms.

Abstract

Many people with an advanced form of kidney disease do not know they have weak or failing kidneys, but early detection and treatment can help prevent the progression of kidney disease to kidney failure. The resulting costs of treatment of ESRD are enormous. ESRD is a complex phenotype, which results from the presence of underlying kidney disease, and superimposing inherited and environmental factors. Among the predisposing genetic factors, renin-angiotensin-aldosterone system (RAAS) disruption is clearly involved in ESRD development. The aim of this study is to evaluate the association between CYP11B2 C-344T and ATR1 A1166C gene polymorphisms with increased risk for ESRD in hypertensive Egyptian patients on maintenance hemodialysis.

This study included 70 ESRD patients on maintenance hemodialysis (32 males and 28 females, mean age 54.5± 9.5 years, recruited from El Doaah and El Rayan hospitals, Cairo, Egypt. 70 healthy individuals, of matching age and sex (30 males and 40 females, mean age 50.2 ± 13.1 years), were also included in the study. All subjects were genotyped for both CYP11B2 C-344T and ATR1 A1166C gene polymorphisms. Serum aldosterone was also measured for all subjects. Concerning the CYP11B2 gene, HD patients showed increased frequency of the TT genotype (68.57%) as compared to controls (only 12.85%), with no significant differences in T allele distribution between the 2 groups. In contrast, HD patients had low frequency of the CC genotype (5.71%) as compared to controls (32.85%), with a significant difference in C allele distribution between the HD patients (28.56%) and controls (70.7%). Comparing serum aldosterone levels in various CYP11B2 genotypes in HD patients revealed that patients with TT genotype had statistically higher aldosterone levels (121.583 ± 43.311) than those with the TC (72.055 ± 11.709) or CC genotype (68.75 ± 13.145). On the other hand, for AT1R A1166C genotype frequency, HD patients showed significantly (p?0.05) higher frequency of CC genotype (70%) than controls (7.1%), with lower AA genotype frequency (5.71%) compared to controls (57%). Moreover, there was significant differences in A allele distribution between the HD patients (27.13%) and controls (64.25%).  The same was true for the C allele, with a frequency of (59.28%) in HD patients compared to a frequency of (39.25%) in controls. On the other hand, studying ATR1 A1166C gene polymorphisms revealed that patients with the CC genotype had significantly higher aldosterone levels (121.25 ± 43.006) than those with AA (87.6 ± 25.4) genotype. 

Author Biographies

Maha Moustafa Kamal, Lecturer of biochemistry

Biochemistry department-Faculty of Science-Ain Shams University-Cairo

Omayma M Hassanin, Assistant consultant of clinical pathology and molecular pathology

 Clinical Pathology, Molecular Biology Department, Medical Research Center, Ain Shams University, Cairo, Egypt

Ezzat Abdel-Rahman El Etreby, Professor of internal medicine and nephrology

Department of Internal medicine and Nephrology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Tarek M El Masry, Assistant consultant of biochemistry and clinical pathology

Department of Clinical Pathology, Ain Shams University Hospitals, Cairo, Egypt

References

[1] Ogata S, Yorioka N, Gilbertson DT, Chen SC, Foley RN, and Collins AJ (2009). “Genetic and environmental effects and characteristics of Japanese end-stage renal disease patients,” Hemodialysis International, vol. 13, supplement 1, pp. S8–S12.
[2] Brewster UC and Perazella MA (2004). “The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease,” American Journal of Medicine, vol. 116, no. 4, pp. 263–272.
[3] Weir MR and Dzau VJ (1999). “The renin-angiotensin-aldosterone system: a specific target for hypertension management,” American Journal of Hypertension, vol. 12, no. 12, part 3, pp. 205S–213S.
[4] Ruster C and Wolf G (2006). “Renin-angiotensin-aldosterone system and progression of renal disease,” Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 2985–2991.
[5] Prasad P, Tiwari AK, and, Kumar KMP (2006). “Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms,” BMC Medical Genetics, vol. 7, article 42.
[6] Yael AN, Hansen JL, Doggen C, Quax PHA, Sheikh SP, and Rosendaal FR (2011). “SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction,” American Journal of Hypertension, vol. 24, no. 9, pp. 999–1006.
[7] Song SB, Jin HS, and Hong KW (2011). “Association between renin-angiotensin-aldosterone system-related genes and blood pressure in a Korean population,” Blood Press, vol. 20, no. 4, pp. 204–210.
[8] Locatelli F, Marcelli D and Comelli M (1996). Proteinuria and blood pressure as causal components of progression to end-stage renal failure: Northern Italian Cooperative Study Group. Nephrol Dial Transplant 11:461–467.
[9] Perry HMJr, Miller JP and Fornoff JR (1995). Early predictors of 15- year end-stage renal disease in hypertensive patients. Hypertension 25:587–594.
[10] Klag MJ, Whelton PK and Randall BL (1996). Blood pressure and end- stage renal disease in men. N Engl J Med 334:13–18.
[11] Buckalew VM Jr, Berg RL and Wang SR (1994). Prevalence of hyper- tension in 1,795 subjects with chronic renal disease: The modifica- tion of diet in renal disease study baseline cohort: Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 28:811–821, mesangial cells. J lin Invest 93:2431–2437.
[12] El-banawy H, Bedair R and Mohammed A (2015). Angiotensin II type 1 receptor (A1166C) gene polymorphism in Egyptian adult hemodialysis Patients. Alexandria journal of medicine. Article in press.
[13] Matsumoto M, Gotoh T, Suzuki-Kusaba M, Yoshida M, Hisa H and Satoh S (2000). Effect of angiotensin II on aldosterone secretion in canine adrenal land in situ. J Cardiovasc Pharmacol. Jul; 36 (1):71-6.
[14] Szpirer C, Riviere M and Szpirer J (1993). Chromosomal assignment of human and rat hypertension candidate genes: type 1 angiotensin II receptor genes and the SA gene. J Hypertens; 11:919-25.
[15] Bonnardeaux A, Davies E and Jeunemaitre X (1994). Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension; 24:63- 9.
[16] Sethupathy P, Borel C and Gagnebin M (2007). Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3’ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet; 81:405-13.
[17] Curnow KM, Tusie-Luna MT and Pascoe L (1991). The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol; 5:1513-22
[18] Makhanova N, Hagaman J, Kim HS and Smithies O (2008). Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension; 51:134-40.
[19] Samavat S, Ahmadpoor P and Samadian F (2011). Aldosterone, hypertension, and beyond. Iran J Kidney Dis. 2011; 5:71-6.
[20] White PC and Rainey WE (2005). Editorial: polymorphisms in CYP11B genes and 11-hydroxylase activity. J Clin Endocrinol Metab. 2005; 90:1252-5
[21] Nicod J, Bruhin D, Auer L, Vogt B, Frey FJ and Ferrari P.A (2003) biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. J Clin Endocrinol Metab.; 88:2495-500.
[22] Brand E, Chatelain N and Mulatero P (1998). Structural analysis and evaluation of the aldosterone synthase gene inhypertensionHypertension; 32:198-204.
[23] Lee JE, Bae SY, Kim JY, Pyo HJ and Kwon YJ (2009). Aldosterone Synthase Gene (CYP11B2) Polymorphism in Korean End-Stage Renal Disease Patients on Hemodialysis Electrolytes Blood Press 7:67-72.
[24] Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P (2001). Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int 60:46-54.
[25] Fabris B, Bortoletto M, and Candido R, (2005). Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension. J Hypertens 23:309-316, 2005.
[26] Su SL, Yang HY, Wu CC, Lee HS, Lin YF, Hsu CA, Lai CH, Lin C, Kao SY and Lu KC (2014). Gene-Gene Interactions in Renin-Angiotensin-Aldosterone System Contributes to End-Stage Renal Disease Susceptibility in a Han Chinese Population. The Scientific World Journal, ID 169798.
[27] Song J, Narita I, and Goto S (2003). “Gender specific association of aldosterone synthase gene polymorphism with renal survival in patients with IgA nephropathy,” Journal of Medical Genetics, vol. 40, no. 5, pp. 372–376.
[28] Pawlik M, Mostowska A, and Lianeri M (2013). “Association of aldosterone synthase (CYP11B2) gene -344T/C polymorphism with the risk of primary chronic glomerulonephritis in the Polish population,” Journal of the Renin-Angiotensin-Aldosterone System.
[29] Hammady MR, Mossaad N, Farhan H and Ali S (2012). Angiotensin II Type 1 Receptor Gene Polymorphism in Egyptian Patients with Chronic Renal Failure. Australian Journal of Basic and Applied Sciences, 6(3): 483-488, ISSN 1991-8178
[30] ChandraS, Narang2 R, Sreenivas V, Bhatia J, Saluja D and Srivastava1 K (2014). Association of Angiotensin II Type 1 Receptor (A1166C) Gene Polymorphism and Its Increased Expression in Essential Hypertension: A Case-Control Study.
[31] Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F (2011) Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens 24: 241–246.
[32] Balakrishnan VS, Rao M, Jaber BL, DialGene C. Genomic medicine, gene polymorphisms, and human biological diversity. Semin Dial 2005; 18:37–40.
[33] Atkinson TJ, Halfon MS. Regulation of gene expression in the genomic context (2014). Comput Struct Biotechnol J; 9:e201401001.
[34] Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, and Elton TS (2007). Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3? untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet; 81:405–13.

Downloads

Published

2015-08-14

How to Cite

Kamal, M. M., Hassanin, O. M., El Etreby, E. A.-R., & El Masry, T. M. (2015). Associations between Human Aldosterone Synthase (CYP11B2) and Angiotensin II type 1 Receptor (ATR1) Gene Polymorphisms with End Stage Renal Disease In hypertensive Egyptian Patients on Maintenance Hemodialysis. American Scientific Research Journal for Engineering, Technology, and Sciences, 14(1), 12–22. Retrieved from https://asrjetsjournal.org/index.php/American_Scientific_Journal/article/view/892